Proparacaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile

Manufacturer
A-S Medication Solutions
Effective date
2021-02-16
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-05-31 20:35:32

Label at a glance#

ProductProparacaine Hydrochloride
Active ingredientPROPARACAINE HYDROCHLORIDE
Label structure12 sections

Indications and uses

Proparacaine Hydrochloride Ophthalmic Solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical...

Dosage and administration

Deep anesthesia as in cataract extraction: Instill 1 drop to the eye every 5 to 10 minutes for 5 to 7 doses. Removal of sutures: Instill 1 or 2 drops to the eye 2 or 3 minutes before removal of stitches. Removal of foreign bodies: Instill 1 or 2 drops to the eye prior to operating. Tonometry: Instill 1 or 2 drops to the eye immediately before measurement.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Sterile

Rx only

DESCRIPTION

DESCRIPTION SECTION

Proparacaine Hydrochloride Ophthalmic Solution USP, 0.5% is a local anesthetic for ophthalmic instillation. Each mL of sterile, aqueous solution contains: Active: Proparacaine Hydrochloride 5 mg (0.5%). Preservative: Benzalkonium Chloride 0.1 mg (0.01%). Inactives: Glycerin as a stabilizer, Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (3.5 to 6.0), and Water for Injection USP.

Proparacaine hydrochloride is designed chemically as 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate monohydrochloride. The active ingredient is represented by the structural formula:

Chemical StructureChemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Proparacaine Hydrochloride Ophthalmic Solution is a rapid acting local anesthetic suitable for ophthalmic use. With a single drop, the onset of anesthesia begins within 30 seconds and persists for 15 minutes or longer.

The main site of anesthetic action is the nerve cell membrane where proparacaine interferes with the large transient increase in the membrane permeability to sodium ions that is normally produced by a slight depolarization of the membrane. As the anesthetic action progressively develops in a nerve, the threshold for electrical stimulation gradually increases and the safety factor for conduction decreases; when this action is sufficiently well developed, block of conduction is produced.

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability by closing the pores through which the ions migrate in the lipid layer of the nerve cell membrane. This limitation prevents the fundamental change necessary for the generation of the action potential.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Proparacaine Hydrochloride Ophthalmic Solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical anesthetic prior to surgical operations such as cataract extraction.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This preparation is contraindicated in patients with known hypersensitivity to any component of the solution.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY.

Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification with accompanying loss of vision.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Proparacaine should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity of proparacaine is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, it should be borne in mind that systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.

Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off. Do not touch dropper tip to any surface as this may contaminate the solution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with Proparacaine Hydrochloride Ophthalmic Solution. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Controlled clinical studies have not been performed with Proparacaine Hydrochloride Ophthalmic Solution to establish safety and effectiveness in pediatric patients; however, the literature cites the use of proparacaine hydrochloride as a topical ophthalmic anesthetic agent in pediatric patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Pupillary dilatation or cycloplegic effects have rarely been observed with proparacaine hydrochloride. The drug appears to be safe for use in patients sensitive to other local anesthetics, but local or systemic sensitivity occasionally occurs. Instillation of proparacaine in the eye at recommended concentration and dosage usually produces little or no initial irritation, stinging, burning, conjunctival redness, lacrimation or increased winking. However, some local irritation and stinging may occur several hours after the instillation.

Rarely, a severe, immediate-type, apparently hyperallergic corneal reaction may occur which includes acute, intense and diffuse epithelial keratitis; a gray, ground-glass appearance; sloughing of large areas of necrotic epithelium; corneal filaments and, sometimes, iritis with descemetitis.

Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.

Softening and erosion of the corneal epithelium and conjunctival congestion and hemorrhage have been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Deep anesthesia as in cataract extraction:

  • Instill 1 drop to the eye every 5 to 10 minutes for 5 to 7 doses.

Removal of sutures:

  • Instill 1 or 2 drops to the eye 2 or 3 minutes before removal of stitches.

Removal of foreign bodies:

  • Instill 1 or 2 drops to the eye prior to operating.

Tonometry:

  • Instill 1 or 2 drops to the eye immediately before measurement.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product: 50090-0259

NDC: 50090-0259-0 15 mL in a BOTTLE, DROPPER / 1 in a CARTON

SPL UNCLASSIFIED SECTION

Akorn
Manufactured by: Akorn, Inc.
Lake Forest, IL 60045

NJPH00N
Rev. 06/16

Proparacaine Hydrochloride

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1191013proparacaine HCl 0.5 % Ophthalmic SolutionPSN8
1191013proparacaine hydrochloride 5 MG/ML Ophthalmic SolutionSCD8
1191013proparacaine hydrochloride 0.5 % Ophthalmic SolutionSY8

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PROPARACAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9ba0893a-4390-4124-b66b-ffd4f2b29a0eProduct name220260305

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
50090-0259-02023-01-30C16284748780-1f386c649-ea2e-0266-e053-dadaa90a7c1aProparacaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50090-0259-0Proparacaine Hydrochloride15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS158
50090-0259-0Proparacaine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS18

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50090-0259PROPARACAINE HYDROCHLORIDE SOLUTION/ DROPS [A-S MEDICATION SOLUTIONS]8Legacy NDC, 2 package rows20210219_40d864dd-ef49-4b05-883b-265a492b4d9c.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-0259-0ML - Milliliter50090-0259a21b473c-843b-41f5-b0f9-0f8bfe50728812021-08-05
17478-263-12ML - Milliliter17478-2630f325a2c-752e-41bf-83e3-f6dea7dbee9c12012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-025950090-0259-0
17478-263

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040277-001PROPARACAINE HYDROCHLORIDEPROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A040277-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1684e616aacf4f…
2026-08-18 06:07:402026-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1631067a03dcf5…
2025-08-23 18:47 UTC2025-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-166a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-162680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-165bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-161e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-168072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-164b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-1674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-1687673890dc5c…
2021-03-12 10:30 UTC2021-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-168869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163f01610625f2…
2019-09-15 20:21 UTC2019-09A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16b00525d2431f…
2019-07-19 19:46 UTC2019-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-166a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-161c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-169b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163f0d92c62455…
2023-05-13 08:27 UTC2023-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16053a50430f4f…
2023-01-26 05:58 UTC2023-01A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A040277-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A040277-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040277-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040277-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040277-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040277-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040277-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040277-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040277-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040277-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040277-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040277-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040277-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040277-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040277-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040277-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040277-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040277-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040277-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040277-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040277-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040277-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040277-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A040277-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040277-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040277-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040277-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A040277-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A040277-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040277-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040277-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040277-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040277-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040277-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040277-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040277-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A040277-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A040277-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040277-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040277-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
3d508ac4-e0df-4467-a8ed-64ebde1cb02d40d864dd-ef49-4b05-883b-265a492b4d9c2021-02-16Warnings, Adverse reactionsExact identifier
spl id: 3d508ac4-e0df-4467-a8ed-64ebde1cb02d
spl set id: 40d864dd-ef49-4b05-883b-265a492b4d9c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.